The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects
Authors:
Open Access
- 22 August 2024
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 33 (10) , 1075-1082
Abstract
BackgroundInhibiting the coagulation factor XI (FXI) is a novel strategy for prevention and treatment of thromboembolism without affecting extrinsic coagulation pathways. SHR-2004 is a humanized monoclonal antibody that selectively binds to FXI and factor XIa (FXIa).Research design & methodsThis randomized, double-blind, dose-escalation, placebo-controlled study evaluated SHR-2004 administered either intravenously (i.v.; Part A) or subcutaneously (s.c.; Part B). In Part A, 24 subjects received a single i.v. dose of SHR-2004 (0.1, 0.3, or 1.0 mg/kg) or placebo. In Part B, 40 subjects received a single s.c. dose of SHR-2004 (0.5, 1.0, 3.0, or 4.5 mg/kg) or placebo.ResultsSHR-2004 was well tolerated. Plasma exposure to SHR-2004 increased in a dose-dependent manner. The geometric mean half-time ranged from 11.6 to 13.0 days. FXI activity decreased, and the activated partial thromboplastin time (APTT) was prolonged after i.v. and s.c. administration in a dose- and time-dependent manner. FXI activity was nearly completely abolished immediately after administering the highest i.v. dose, with the average APTT prolonged to nearly three times of baseline.ConclusionSHR-2004 is a promising candidate for further development as an anticoagulant drug that exerts effective anticoagulation with minimal risk of bleeding.Clinical trial registrationwww.clinicaltrials.gov identifier is NCT05369767.Keywords
Funding Information
- National Natural Science Foundation of China (No. 31371399)
This publication has 17 references indexed in Scilit:
- BJTJ-1837, a novel FXI activation-blocking antibodyResearch and Practice in Thrombosis and Haemostasis, 2023
- Factor XI DeficiencyHematology/Oncology Clinics of North America, 2021
- Factor XI Inhibition to Uncouple Thrombosis From HemostasisJACC, 2021
- Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee ArthroplastyJAMA, 2020
- BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokineticsResearch and Practice in Thrombosis and Haemostasis, 2019
- An update on factor XI structure and functionThrombosis Research, 2018
- Treatment of Venous Thromboembolism With New Anticoagulant AgentsJACC, 2016
- The mechanism underlying activation of factor IX by factor XIaThrombosis Research, 2014
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012